Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 98

Sort by

Sort Order Select

Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood (2024) 144 (23): 2389–2401.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Cardiac Glycosides Induce Immunogenic Changes in Myeloma Cells and Enhance the Efficacy of Monoclonal and Bispecific Antibody Therapy

Tomoyuki Nakamura, Masaki Ri, Toru Ebina, Yoshiaki Marumo, Yoshiko Oshima, Hirokazu Sasaki, Arisa Asano, Shiori Kinoshita, Tomotaka Suzuki, Tomoko Narita, Takaomi Sanda, Hirokazu Komatsu, Yasumichi Inoue, Hidetoshi Hayashi, Shinsuke Iida

Blood (2024) 144 (Supplement 1): 6813.

https://doi.org/10.1182/blood-2024-200981

Published: 2024

Journal Articles

Genetic Alterations in Primary and Secondary Plasma Cell Leukemia: A Comparative Study Involving Patients with Non-PCL Myeloma

Yoko Nakanishi, Tomotaka Suzuki, Takashi Kanamori, Hirokazu Sasaki, Arisa Asano, Shiori Kinoshita, Tomoko Narita, Takaomi Sanda, Masaki Ri, Hirokazu Komatsu, Shinsuke Iida

Blood (2024) 144 (Supplement 1): 6842.

https://doi.org/10.1182/blood-2024-200672

Published: 2024

Journal Articles

Targeting Overexpressed IDO on Stromal Cells As a Potential Therapeutic Strategy in Multiple Myeloma

Toru Ebina, Masaki Ri, Yoshiko Oshima, Tomoyuki Nakamura, Yoshiaki Marumo, Hirokazu Sasaki, Arisa Asano, Shiori Kinoshita, Tomotaka Suzuki, Tomoko Narita, Ayako Masaki, Takaomi Sanda, Hirokazu Komatsu, Hirotake Sakuraba, Shinsuke Iida

Blood (2024) 144 (Supplement 1): 4638.

https://doi.org/10.1182/blood-2024-199941

Published: 2024

Journal Articles

A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Sueh-Li Lim, Bradley Augustson, Hira S Mian, Edward A. Stadtmauer, Shinsuke Iida, Michael Slade, Saswati Hazra, Kamal Chamoun, Patricia Cheung, Jamal Saeh, Nina Shah, Amrita Y Krishnan

Blood (2024) 144 (Supplement 1): 2000.2.

https://doi.org/10.1182/blood-2024-207816

Published: 2024

Journal Articles

The Impact of MYD88 and/or CD79B Gene Mutations on Central Nervous System Relapse in Patients with Diffuse Large B-Cell Lymphoma

Tomotaka Suzuki, Keiichiro Fujii, Naohiro Matsunaga, Hirokazu Sasaki, Takashi Kanamori, Arisa Asano, Shiori Kinoshita, Tomoko Narita, Ayako Masaki, Takaomi Sanda, Masaki Ri, Hirokazu Komatsu, Shinsuke Iida, Hiroshi Inagaki

Blood (2024) 144 (Supplement 1): 3075.

https://doi.org/10.1182/blood-2024-198325

Published: 2024

Journal Articles

Pooled Efficacy and Safety of Teclistamab in 217 Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from 3 Registrational Clinical Studies

Blood (2024) 144 (Supplement 1): 3331.

https://doi.org/10.1182/blood-2024-200354

Published: 2024

Journal Articles

Stratifying ‘frail’ Patients Defined By the Simplified Frailty Scale in Multiple Myeloma: Correlation with Clinical Outcomes

Yukiyasu Kato, Tomotaka Suzuki, Aki Kondo, Naohiro Matsunaga, Takaki Kikuchi, Takashi Kanamori, Takashi Yoshida, Satoshi Kayukawa, Yu Asao, Hiroki Yano, Hirokazu Sasaki, Arisa Asano, Shiori Kinoshita, Tomoko Narita, Takaomi Sanda, Masaki Ri, Hirokazu Komatsu, Shinsuke Iida

Blood (2024) 144 (Supplement 1): 3342.

https://doi.org/10.1182/blood-2024-201310

Published: 2024

Journal Articles

Treatment and Outcomes of Stage I-II Pulmonary MALT Lymphoma: A Multi-Institutional Observational Study in Japan

Blood (2024) 144 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2024-198992

Published: 2024

Journal Articles

Prognostic Impact of Clinical Factors and Cell Composition of Apheresis Samples on BCMA CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma

Yoshiaki Marumo, Masaki Ri, Toru Ebina, Tomoyuki Nakamura, Hirokazu Sasaki, Shiori Kinoshita, Tomoko Narita, Tomotaka Suzuki, Takaomi Sanda, Takanori Nanri, Hirokazu Komatsu, Shinsuke Iida

Blood (2024) 144 (Supplement 1): 2411.6.

https://doi.org/10.1182/blood-2024-200675

Published: 2024

Journal Articles

MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Matthew Pianko, Charlotte Pawlyn, Shang-Yi Huang, Tadao Ishida, Douglas W Sborov, Shinsuke Iida, Aravind Ramakrishnan, Reuben Benjamin, Rakesh Popat, Steven Schuster, Junya Kuroda, Chia-Jen Liu, Anne Philippe, Umberto Conte, Fangxin Hong, Erik Vandendries, Rafael Fonseca

Blood (2024) 144 (Supplement 1): 4743.

https://doi.org/10.1182/blood-2024-205872

Published: 2024

Journal Articles

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Blood (2024) 143 (23): 2401–2413.

https://doi.org/10.1182/blood.2023022540

Published: 2024

Includes: Supplemental data

Journal Articles

Applying Artificial Intelligence Machine Learning to Discover Factors That Shorten Duration of Treatment in Patients with Multiple Myeloma Using Real-World Patient-Level Longitudinal Data from Medical Data Vision Database

Hiroshi Handa, Tadao Ishida, Shuji Ozaki, Shinsuke Iida, Asuka Mori, Chika Sakai, Kenichi Kato, David Bin-Chia Wu, DaeYoung Yu, Shota Nemoto, Yasuho Yamashita, Takuma Shibahara

Blood (2023) 142 (Supplement 1): 6665.

https://doi.org/10.1182/blood-2023-172849

Published: 2023

Journal Articles

Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 Trial

Blood (2023) 142 (Supplement 1): 4866.

https://doi.org/10.1182/blood-2023-178778

Published: 2023

Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Blood (2023) 142 (Supplement 1): 1028.

https://doi.org/10.1182/blood-2023-178933

Published: 2023

Journal Articles

Final Analysis of the Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab for DLBCL: JCOG0601

Blood (2023) 142 (Supplement 1): 1724.

https://doi.org/10.1182/blood-2023-178551

Published: 2023

Journal Articles

Long-Term Efficacy and Safety of Elranatamab Monotherapy in the Phase 2 Magnetismm-3 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

Michael Tomasson, Shinsuke Iida, Ruben Niesvizky, Mohamad Mohty, Nizar J Bahlis, Joaquin Martinez-Lopez, Guenther Koehne, Paula Rodriguez Otero, H. Miles Prince, Andrea Viqueira, Eric Leip, Umberto Conte, Sharon T Sullivan, Alexander Lesokhin

Blood (2023) 142 (Supplement 1): 3385.

https://doi.org/10.1182/blood-2023-182130

Published: 2023

Journal Articles

Whole Exome Sequencing Analysis of Diffuse Large B-Cell Lymphoma That Progressed to Central Nervous System

Tomotaka Suzuki, Rui Yokomori, Takaomi Sanda, Hiroki Yano, Takaki Kikuchi, Takashi Kanamori, Atsushi Inagaki, Takashi Yoshida, Satoshi Kayukawa, Yoshiko Oshima, Hirokazu Sasaki, Shiori Kinoshita, Tomoko Narita, Ayako Masaki, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Hiroshi Inagaki, Shinsuke Iida

Blood (2023) 142 (Supplement 1): 1632.

https://doi.org/10.1182/blood-2023-174341

Published: 2023

Journal Articles

The hepatic niche leads to aggressive natural killer cell leukemia proliferation through the transferrin–transferrin receptor 1 axis

Blood (2023) 142 (4): 352–364.

https://doi.org/10.1182/blood.2022018597

Published: 2023

Includes: Supplemental data

Journal Articles

Circulating miRNA Profiling of Plasma Samples from Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study to Predict the Response and Toxicity of Bortezomib-Containing Regimen: An Ancillary Study of JCOG1105 (JCOG1105A1)

Masaki Ri, Shimon Nakashima, Miki Nakajima, Shinsuke Iida, Dai Maruyama, Satoshi Osaga, Kensei Tobinai, Noriko Fukuhara, Kana Miyazaki, Norifumi Tsukamoto, Hideki Tsujimura, Makoto Yoshimitsu, Kenichi Miyamoto, Kunihiro Tsukasaki, Hirokazu Nagai

Blood (2022) 140 (Supplement 1): 12647–12649.

https://doi.org/10.1182/blood-2022-156875

Published: 2022

NARROW

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Cardiac Glycosides Induce Immunogenic Changes in Myeloma Cells and Enhance the Efficacy of Monoclonal and Bispecific Antibody Therapy

Genetic Alterations in Primary and Secondary Plasma Cell Leukemia: A Comparative Study Involving Patients with Non-PCL Myeloma

Targeting Overexpressed IDO on Stromal Cells As a Potential Therapeutic Strategy in Multiple Myeloma

A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

The Impact of MYD88 and/or CD79B Gene Mutations on Central Nervous System Relapse in Patients with Diffuse Large B-Cell Lymphoma

Pooled Efficacy and Safety of Teclistamab in 217 Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from 3 Registrational Clinical Studies

Stratifying ‘frail’ Patients Defined By the Simplified Frailty Scale in Multiple Myeloma: Correlation with Clinical Outcomes

Treatment and Outcomes of Stage I-II Pulmonary MALT Lymphoma: A Multi-Institutional Observational Study in Japan

Prognostic Impact of Clinical Factors and Cell Composition of Apheresis Samples on BCMA CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma

MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Applying Artificial Intelligence Machine Learning to Discover Factors That Shorten Duration of Treatment in Patients with Multiple Myeloma Using Real-World Patient-Level Longitudinal Data from Medical Data Vision Database

Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 Trial

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Final Analysis of the Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab for DLBCL: JCOG0601

Long-Term Efficacy and Safety of Elranatamab Monotherapy in the Phase 2 Magnetismm-3 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

Whole Exome Sequencing Analysis of Diffuse Large B-Cell Lymphoma That Progressed to Central Nervous System

The hepatic niche leads to aggressive natural killer cell leukemia proliferation through the transferrin–transferrin receptor 1 axis

Circulating miRNA Profiling of Plasma Samples from Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study to Predict the Response and Toxicity of Bortezomib-Containing Regimen: An Ancillary Study of JCOG1105 (JCOG1105A1)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only